Nurse Practitioner Program year 2024 Reported 2022–2024 Source: CMS Open Payments, 2026 publication

Tamara Ruoff

Registered Nurse Lincoln, NE Nurse Practitioner

NPI 1184360646 CMS profile 11349676

4825 Cresthaven Dr, Lincoln, NE 68516

Open in the dashboard

General payments

$405

18 records reported · program years 2022–2024

Research payments

$0

Paid to them · None reported · program years 2022–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Tamara Ruoff of Lincoln, NE is reported in the CMS Open Payments database as having received $405 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $270 11
2022 General $118 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tamara Ruoff
  • Registered Nurse median
  • Middle half of Registered Nurse
  • National median

In program year 2025, general payments to Tamara Ruoff were reported at $0. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.

Show as a table
Year Tamara Ruoff Registered Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $53 $20–$148 $132
2022 $118 $53 $21–$146 $149
2023 $270 $84 $26–$196 $160
2024 $17 $80 $26–$187 $164
2025 $0 $74 $27–$193 $169

Breakdown

Who paid General payments · program years 2022–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $100 3 payments
  2. Pfizer Inc. $94 5 payments
  3. Abiomed $77 2 payments
  4. AstraZeneca Pharmaceuticals LP $72 5 payments
  5. Janssen Pharmaceuticals, Inc $62 3 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2024
  1. Food and Beverage $405 18 payments
Products named General payments · program years 2022–2024
  1. JARDIANCE $100 3 payments
  2. ELIQUIS $94 5 payments
  3. PAXLOVID $94 5 payments
  4. Impella $77 2 payments
  5. XARELTO $62 3 payments
  6. FARXIGA $58 4 payments
  7. NURTEC ODT $54 3 payments
  8. ZAVZPRET $22 1 payment
  9. BRILINTA $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

682

Median for Nurse Practitioner: 389

Drug cost

$59,552

Median for Nurse Practitioner: $21,885

Branded share of claims

30.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 42 $23,898
Xarelto Rivaroxaban Brand 21 $11,795
Farxiga Dapagliflozin Propanediol Brand 14 $7,360
Jardiance Empagliflozin Brand 12 $6,877
Brilinta Ticagrelor Brand 11 $4,682
Prasugrel Hcl Generic 19 $673
Metoprolol Succinate Generic 65 $596
Clopidogrel Clopidogrel Bisulfate Brand 98 $564
Nebivolol Hcl Generic 12 $562
Pantoprazole Sodium Generic 62 $452

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$37,470

Of which drugs: $8,319

Medicare patients

329

Average age 74

Services billed

680

176 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 33%
Atrial fibrillation 27%
Diabetes 22%
Depression 22%
Heart failure 21%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 24 24 $7,010
Vaccine for influenza for injection into muscle 90662 Office 16 16 $1,309

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record